Why Organizations Should Join the Coalition
Patient Advocacy Organizations
The investments made in early stage research by the NIH are the basis for future discovery for many of the hardest to understand, most complicated diseases and conditions. For many patient advocates, NIH funding is the only source of funding available to support researchers. Whether it is tackling a rare disease in children or a more common one like Alzheimer’s, most people mistakenly believe private industry does this research, but the bulk of early stage research is funded by the NIH.
When the NIH has the proper funding for research, lives are improved. The proposed NIH funding cuts leave patients vulnerable by drastically reducing the amount of potentially life-saving research that will be conducted. The patient perspective is critical when it comes to discussions around the importance of funding research. Too often the technical details of research are too complicated for busy policymakers to master, but they can grasp the hope research offers and they can understand the need NIH funding fills. Patient advocacy groups can come together with other healthcare leaders and lend their voice in the fight to protect research funding, ensuring the difference between success and failure.
Pharmaceutical and Biotech Companies
Pharmaceutical and biotech companies are continually engaging in the research and development of innovative treatments for patients across a spectrum of diseases. The product pipelines of pharmaceutical and biotech companies across the country, which often build on basic research done by NIH funded scientists, will be affected by drastic cuts in researching funding, putting future breakthroughs at risk.
Investing in biomedical research is essential to reaching the ultimate goal of alleviating the burden of disease. Pharmaceutical companies can help give a voice to illustrate the negative consequences of drastic funding cuts. This Coalition provides the opportunity to work with like-minded organizations to bring about change in the perception among lawmakers that early stage research funding is not important or that it is the type of research done by pharmaceutical and bio/tech companies.
Medical Device Companies
Any successful medical device can be traced back to an innovative research and development idea and collaboration. The NIH plays a critical role in helping to ensure that the research pathway remains rich. Companies on the front lines of developing and marketing cutting-edge medical devices must be a part of discussions to ensure their perspective is heard.
The medical device industry brings technology solutions to millions of patients on a daily basis and their pipeline of research cannot afford to be disrupted – there is too much at stake. Join fellow industry leaders to protect the innovation pipeline that is at the heart of what makes America a leader in medical innovation.
With more than 80 percent of the NIH’s annual budget going to support 2,500 research universities and organizations, it is clear why the proposed budget cuts are of the highest concern for research institutions across the country. NIH funding is a vital part of the lifeblood of the nation’s leading research universities and allows for cutting-edge advancements to be made by the brightest scientific minds. The NIH funding cuts directly threaten the United States’ leadership in academic-driven research. As an important beneficiary of NIH support, it is imperative that research universities lend their voice to this important coalition to ensure that medical and scientific research continues to flourish and drive healthcare innovation.